Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Developmental Delay and Refusal to Walk in an Infant.
Krupadev V, Thomas V, Dahr SE, Warrier R. Krupadev V, et al. Clin Pediatr (Phila). 2021 Feb;60(2):134-138. doi: 10.1177/0009922820972202. Epub 2020 Nov 11. Clin Pediatr (Phila). 2021. PMID: 33174461 No abstract available.
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N. Coletta AM, et al. Among authors: thomas vm. BMC Cancer. 2024 Apr 18;24(1):493. doi: 10.1186/s12885-024-12260-3. BMC Cancer. 2024. PMID: 38637770 Free PMC article.
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: thomas vm. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: thomas vm. Prostate Cancer Prostatic Dis. 2023 Aug 24. doi: 10.1038/s41391-023-00706-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37620429 No abstract available.
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: thomas vm. Prostate Cancer Prostatic Dis. 2023 Jul 17. doi: 10.1038/s41391-023-00696-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37460732
Incorporating New Technologies in EEIO Models.
Azuero-Pedraza CG, Thomas VM, Ingwersen WW. Azuero-Pedraza CG, et al. Among authors: thomas vm. Appl Sci (Basel). 2022 Jul 12;12(14):7016. doi: 10.3390/app12147016. Appl Sci (Basel). 2022. PMID: 36310540 Free PMC article.
59 results